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A 57-year-old male who had been treated for granulomatosis with polyangiitis (GPA) presented with
cough and back pain that had persisted for three days. Mild inﬁltration shadows and nodules were found
on computed tomography images at that time. Increase of GPA lesions and/or bacterial pneumonia was
initially suspected. However, serum Cryptococcus neoformans antigen was positive and the chest X-ray
ﬁndings had worsened by the following day despite of appropriate antibiotic treatment. Thus, pneu-
monia due to C. neoformans was diagnosed because C. neoformans was also isolated blood and lung
tissues, and he was treated with antifungal agents: L-AMB and 5-FC, and followed up by chest radiog-
raphy on a daily basis.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Cryptococcus neoformans (C. neoformans) is an encapsulated
fungus found in soil that is associated with bird droppings, espe-
cially pigeons [1e3].
Cell-mediated immunity is essential in controlling cryptococcal
infections, and it is considered an opportunistic pathogen because
infections occur primarily in patients with profoundly impaired
cell-mediated immunity although C. neoformans sometimes infects
immunocompetent hosts [2].
Here, we describe rapidly progressive and lobar pneumonia
caused by C. neoformans that could be followed up as changes in
chest X-ray ﬁndings.
Case report
A 57-year-old man who was administered with oral methyl
prednisolone 20 mg/day and methotrexate to treat granulomatosis
with polyangiitis (GPA) visited at our emergency department on
December 2013 with acute back pain around the left shoulder andtrol and Prevention, Osaka
565-0871, Japan. Tel.: þ81 6
.jp, sekimm-ngs@umin.ac.jp
Ltd. This is an open access article umild fever accompanied by fatigue that had persisted for three
days. The GPA seemed to be controlled because the level of PR3-
ANCA, a common biomarker of GPA, was increased to 6.3 IU/mL
(<3.5 IU/mL) for a few months, but not signiﬁcantly increased at
that time.
A physical examination indicated the following: temperature,
37.9 C; blood pressure,132/82mmHg; respiratory rate, 24 breaths/
min (O2 2 L), but it did not reveal crackles and opacity was not
found on chest radiographs on Day 1 (Fig. 1A). However, chest
computed tomography (CT) indicated a mild inﬁltration shadow in
the left dorsal lobe (Fig. 2). His initial WBC count was 11,550/mL and
the C-reactive protein (CRP) level was 5.67 mg/dL. Bacterial pneu-
monia was initially suspected, and then sputum, urine and blood
samples were collected to detect the pathogens, and tosuﬂoxacin
450 mg/day was administered and he went back.
However, he presented again on the following day (Day 2) with
increased back pain. Chest radiography at this time revealed sig-
niﬁcant lobar shadows (Fig. 1B). We initially suspected bacterial
pneumonia and started antibiotic therapy: meropenem 1 g  3
times/day on admission. But serum that had been collected on the
previous day was positive for Cryptococcus antigen (512). Binax
Now rapid antigen tests for inﬂuenza A and B virus, Streptococcus
pneumoniae and Legionella species (Binax, Portland, OR, USA) were
negative. The QuantiFERON-TB Gold test (Quest Diagnostics, Mad-
ison, CT, USA) for tuberculosis was negative. In addition, we could
not found any pathogenic bacteria on both gram staining and cul-
ture of his sputum. Therefore, we suspected rapidly progressivender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Chest radiography images of 57-year-old patient admitted with C. neoformans pneumonia in December 2013. Image on Day 1 shows no speciﬁc shadows (A), but inﬁltration
shadows (arrows) on left middle ﬁeld and dullness of left costophrenic angle appeared on Day 2 (B), and remained rapidly progressive on Day 4 (C). These ﬁndings gradually
improved on Days 8 (D), 15 (E) and 20 (F).
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FLCZ) 400 mg/day. Two days later, C. neoformanswas cultured from
both sputum and blood samples (Fig. 3A).
Although increase of GPA lesions, which make similar granu-
loma with Cryptococcus infection, was also suspected, we detected
signiﬁcant numbers of C. neoformans by transbronchial biopsy
(TBB) of the left lower lobe by bronchoscopy examination (Fig. 3B),
and ﬁnally diagnosed his main pathogenicity as acute lobar pneu-
monia by C. neoformans.
We did not detect C. neoformans in cerebrospinal ﬂuid (CSF),
which appeared essentially normal (pressure, 140mmH2O; cells, 2/
mL; protein, 19 mg/dL; glucose, 70 mg/dL) and negative for Cryp-
tococcus antigen, but we changed fos-FLCZ to liposomal-
amphotericin B (5 mg/kg/day) plus 5-FC (4  25 mg/kg/day) at
Day 2, and continued for two weeks followed by ﬂuconazoleFig. 2. Chest computed tomography images at Day 1. Inﬁltration shadow and nodules
are evident (arrows).(200 mg/day) according to severe cryptococcal infection cases. The
susceptibility of the isolated C. neoformans to antifungal drugs
(minimum inhibitory concentration; MIC) was as follows: AMPH-B
(0.5 mg/mL), 5-FC (8 mg/mL), FLCZ (2 mg/mL), VRCZ (0.03 mg/mL), and
MCFG (>16 mg/mL), respectively, and blood cultures became
negative on Day 11.
Signs on chest radiograms worsened until Day 4 (Fig. 1C), but
improved daily until day 20 (Fig. 1E and F).Discussion
Disease related to C. neoformans or Cryptococcus gattii has
become increasingly prevalent in immunocompromised patients,
including those with AIDS, although pulmonary cryptococcosis has
been isolated sometimes from apparently immunocompetent pa-
tients. Infectionwith C. neoformans ﬁrst occurs after inhaling fungal
basidiospores. A small focal pneumonitis then develops that may or
may not be symptomatic [2,4]. The clinical manifestations of pul-
monary cryptococcosis include localized nodular lesions with or
without cavitations, segmental pneumonic inﬁltrates, patchy
interstitial or alveolar inﬁltrates, pleural effusions, hilar masses and
thoracic lymphadenopathy [1,4].
Our patient had progressive, localized disease with a mild to
moderate systemic inﬂammatory response and an initial indolent
presentation. Chest radiography showedmild nodules and inﬁltrate
on Day 1 that rapidly worsened on Days 2 and 4. These ﬁndings
suggested acute or its on chronic C. neoformans infection in this
patient. He was HIV-negative, but was under corticosteroid therapy
for GPA, which is pathologically similar to granulomata and appears
as radiographic nodules. His CD4 cell counts decreased to 116/uL
because methotrexate had been administered to treat worsening
GPA. Thus, he might have been immunocompromised, and sus-
ceptible to progressive lobar types of pneumonia. Macrophages and
lymphocytes might be inactivated, and levels of immunoglobulin G
(IgG), IgA, and IgM in the blood have been decreased [5]. Our pa-
tient had low IgG levels (585 mg/dL) which required occasional
supplementation, and this factor also might accelerate the progress
of C. neoformans pneumonia in this patient. In addition, cortico-
steroid had increased the level of HbA1c, an indicator of diabetes
mellitus, to 8.0% (NGSP), which supported the notion that he was in
fact immunocompromised. Symptoms and radiographic signs also
worsened in our patient within a few days. Such changes might be
Fig. 3. Cryptococcus detected in blood and lung tissues. Unstained yeasts are surrounded by empty space (arrows in blood stained with India ink preparation; magniﬁcation 1000
(A). Yeasts are visualized with Grocott stain in lung tissue samples collected by bronchoscopy; magniﬁcation 400 (B).
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[3,4,6,7] although it can progress over days instead of weeks in
hosts with extreme immunosuppression such as thosewith AIDS or
under medication with high-dose corticosteroid and/or cyclo-
phosphamide [2].
In this case, we detected C. neoformans in sputum, blood and in
TBB specimens of inﬁltrated lesions. These ﬁndings together with
laboratory data support the notion that the pathogenicity and
radiographic changes were mainly due to C. neoformans infection
rather than GPA exacerbation. In addition, PR3-ANCA did not
change, but levels of cryptococcal antigen, which has >90% sensi-
tivity and speciﬁcity, was increased [2]. The presence of
C. neoformans antigen should be always assessed when patients
present with the immunocompromised conditions, although
worsening GPA and related pulmonary lesions might be suspected.
Patients with symptomatic cryptococcal pneumonia can present
with cough, chest pain, increased sputum production, fever, weight
loss and hemoptysis. In contrast, the ratio of patients with
asymptomatic pulmonary cryptococcosis is about 30% and infection
is incidentally discovered in such patients [2,4]. Biopsy specimens
from symptomatic patients with chest radiographic ﬁndings indi-
cating malignancy occasionally reveal cryptococcosis. Global
ecological studies have found C. neoformans in soil samples from
around the world in areas frequented by birds, especially pigeons
and chickens. Our patient lived close to a park that was populated
by ﬂocks of pigeons.
Fluconazole is active against C. neoformans, easily administered,
and has safe proﬁles. Candidates for treatment are those with
persistent and/or disabling symptoms, multiple nodules or exten-
sive inﬁltrates on chest X-rays, and/or positive serum cryptococcal
antigen ﬁndings. However, we administered liposomal AMPH-B
and 5-FC according to the severe cryptococcal condition cases.
Additional studies are needed to more precisely determine the role
of AMPH-B and 5-FC followed by ﬂuconazole in treating severe or
rapidly progressive pulmonary cryptococcosis in immunocompro-
mised patients as well as the optimal dosage and duration of
therapy. The optimal ﬂuconazole dosage has not been deﬁned. Adaily dose of 200e400 mg, and induction with 600 mg for four
weeks, followed by 200 mg for 10e12 weeks have been adminis-
tered [8]. Our patient was treatedwith oral ﬂuconazole 200mg/day
after two weeks AMPH-B and 5-FC. At the four-month follow up,
the general condition of our patient was obviously improved and
chest X-rays have repeatedly shown that the mass in the lower lobe
lung continues to decrease.
In conclusion, we described rapidly progressive cryptococcal
pneumonia that was clinically and radiologically improved by
treatment with liposomal L-AMPB and 5-FC. The time course was
followed up by chest X-rays to detect radiographic changes.
Symptoms appeared only three days before admission and chest X-
ray ﬁndings became abnormal within a few days thereafter. We
detected C. neoformans from blood and lung samples, which ﬁnally
distinguished the infection from GPA exacerbation. However,
further studies, including accurate diagnosis of C. neoformans and
the mechanism of rapid progression under various immunological
and microbiological backgrounds are required.References
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